Table 2 Frequency of adverse reactions in each treatment cohort [case, number of subjects (%)]
Canocapavir | Placebo | |||||||
|---|---|---|---|---|---|---|---|---|
50 mg, n = 8 | 100 mg, n = 8 | 200 mg, n = 8 | n = 6 | |||||
case | n (%) | case | n (%) | case | n (%) | case | n (%) | |
Total | 6 | 3 (37.5) | 10 | 5 (62.5) | 8 | 4 (50) | 7 | 3 (50) |
Increased alanine aminotransferase | 2 | 2 (25) | 3 | 3 (37.5) | 3 | 3 (37.5) | 3 | 3 (50) |
Increased aspartate aminotransferase | 1 | 1 (12.5) | 2 | 2 (25) | 1 | 1 (12.5) | 4 | 3 (50) |
Decreased white blood cell count | 1 | 1 (12.5) | 1 | 1 (12.5) | 0 | 0 (0) | 0 | 0 (0) |
Decreased neutrophil count | 1 | 1 (12.5) | 1 | 1 (12.5) | 0 | 0 (0) | 0 | 0 (0) |
Increased γ-glutamyltransferase | 0 | 0 (0) | 1 | 1 (12.5) | 0 | 0 (0) | 0 | 0 (0) |
Increased bilirubin | 0 | 0 (0) | 0 | 0 (0) | 1 | 1 (12.5) | 0 | 0 (0) |
Increased creatinine | 1 | 1 (12.5) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
Decreased platelet count | 0 | 0 (0) | 1 | 1 (12.5) | 0 | 0 (0) | 0 | 0 (0) |
Decreased serum phosphorus | 0 | 0 (0) | 0 | 0 (0) | 1 | 1 (12.5) | 0 | 0 (0) |
Hypertriglyceridemia | 0 | 0 (0) | 0 | 0 (0) | 2 | 1 (12.5) | 0 | 0 (0) |
Rash | 0 | 0 (0) | 1 | 1 (12.5) | 0 | 0 (0) | 0 | 0 (0) |